Raymon Aggarwal, MD
Internal Medicine · Dallas, TXNPI 1821007279
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,419 of the $15,677 with a category attached, or 72.8%. 50 manufacturers reported payments, led by Amgen at 36.4% of the total. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Amarin Pharma, Inc.$871
- Novo Nordisk$765
- Atricure, Inc.$721
- Siemens Medical Solutions USA, Inc.$628
- Abbott$593
- plus $6K from 44 others
What the payments were for
- Speaking & faculty fees$4,18027%
- Travel & lodging$350%
- Food & beverage$11,41973%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$4,180
- ATRICLIP LAA EXCLUSION SYSTEM$446
- EVENITY$427
- INVOKANA$370
- WatchPATONE$349
- SOMATOM go.Top$230
- SYMPLICITY G3$158
- MAGNETOM Free.Max$140
- RYBELSUS$125
- PRALUENT$125
- NURTEC ODT$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$122
- FREESTYLE LIBRE 3$121
- ACCRUFER$120
- MYRBETRIQ$119
- Wegovy$118
- Vascepa$115
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$115
- ELIQUIS$111
- KISUNLA$107
How this compares
$15,677 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $107,648 |
| JardianceEmpagliflozin | 65 | $70,270 |
| MounjaroTirzepatide | 43 | $63,939 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 165 | $52,594 |
| XareltoRivaroxaban | 25 | $32,296 |
| Repatha SureclickEvolocumab | 46 | $31,367 |
| Wellbutrin XlBupropion Hcl | 12 | $31,127 |
| OzempicSemaglutide | 15 | $18,485 |
| MyrbetriqMirabegron | 12 | $15,996 |
| RybelsusSemaglutide | 15 | $13,806 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $12,870 |
| SynthroidLevothyroxine Sodium | 118 | $10,467 |
| RestasisCyclosporine | 13 | $10,451 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $8,354 |
| EdarbiAzilsartan Medoxomil | 12 | $7,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $371 | $109,077179 claims |
| Boehringer IngelheimJardiance | $124 | $70,27065 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $205 | $67,146208 claims |
| Lilly USA, LLCMounjaro | $470 | $63,93943 claims |
| Johnson & JohnsonXarelto | $541 | $32,29625 claims |
| Novo NordiskOzempic, Rybelsus | $765 | $32,29130 claims |
| AbbVieSynthroid, Restasis | $398 | $20,918131 claims |
| Astellas Pharma US IncMyrbetriq | $314 | $15,99612 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $323 | $12,87015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.